The stock price of Revolution Medicines Inc (NASDAQ: RVMD) has jumped by 10.98 compared to previous close of 37.66. Despite this, the company has seen a gain of 2.85% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-07 that Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Ryan Asay – Senior Vice President-Corporate Affairs Mark Goldsmith – Chairman and Chief Executive Officer Steve Kelsey – President-Research and Development Wei Lin – Chief Medical Officer Jack Anders – Chief Financial Officer Conference Call Participants Michael Schmidt – Guggenheim Marc Frahm – TD Cowen Eric Joseph – J.P. Morgan Jonathan Chang – Leerink Partners Kelly Shi – Jefferies Ellie Merle – UBS Operator Good day, and thank you for standing by.
Is It Worth Investing in Revolution Medicines Inc (NASDAQ: RVMD) Right Now?
Moreover, the 36-month beta value for RVMD is 1.13. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVMD is 161.98M and currently, short sellers hold a 10.14% of that float. On May 08, 2025, RVMD’s average trading volume was 1.66M shares.
RVMD’s Market Performance
The stock of Revolution Medicines Inc (RVMD) has seen a 2.85% increase in the past week, with a 34.26% rise in the past month, and a -4.07% fall in the past quarter. The volatility ratio for the week is 4.55%, and the volatility levels for the past 30 days are at 5.47% for RVMD. The simple moving average for the past 20 days is 9.43% for RVMD’s stock, with a -5.03% simple moving average for the past 200 days.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $62 based on the research report published on July 16, 2024 of the previous year 2024.
Barclays, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $52. The rating they have provided for RVMD stocks is “Overweight” according to the report published on July 12th, 2024.
Jefferies gave a rating of “Buy” to RVMD, setting the target price at $63 in the report published on July 08th of the previous year.
RVMD Trading at 11.15% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.02% of loss for the given period.
Volatility was left at 5.47%, however, over the last 30 days, the volatility rate increased by 4.55%, as shares surge +20.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.27% upper at present.
During the last 5 trading sessions, RVMD rose by +3.91%, which changed the moving average for the period of 200-days by -11.91% in comparison to the 20-day moving average, which settled at $38.22. In addition, Revolution Medicines Inc saw -4.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from Cislini Jeff, who sale 2,041 shares at the price of $38.71 back on Mar 20 ’25. After this action, Cislini Jeff now owns 57,723 shares of Revolution Medicines Inc, valued at $79,008 using the latest closing price.
JEFFREY TODD CISLINI, the Officer of Revolution Medicines Inc, proposed sale 2,041 shares at $38.75 during a trade that took place back on Mar 20 ’25, which means that JEFFREY TODD CISLINI is holding shares at $79,089 based on the most recent closing price.
Stock Fundamentals for RVMD
The total capital return value is set at -0.29. Equity return is now at value -29.33, with -25.58 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -4.1.
Currently, EBITDA for the company is -589.02 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.20.
Conclusion
To wrap up, the performance of Revolution Medicines Inc (RVMD) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
